Introduction
Inflammatory bowel disease (IBD) is a collection of chronic diseases of the bowel, including ulcerative colitis and Crohn's disease. Incidence estimates suggest that 5-6 children per 100,000 are diagnosed with IBD annually (Lindberg, Lindquist, Holmquist, & Hildebrand, 2000) . Patients with IBD experience changes in stool frequency and composition, including constipation and diarrhea, combined with pain or discomfort in the abdomen due to bloating or a sensation of incomplete voiding. According to the most recent estimates, IBD costs 1.8-2.6 billion in ER and office visits, medications, lost work time, and hospitalizations (Hay & Hay, 1992) . Similar to other chronic illnesses, IBD appears to negatively impact children's social, school, physical, and emotional functioning (Lix et al., 2008; Sawyer et al., 2004) . IBD treatments aim to manage and suppress symptoms, with the goal being long-term remission.
Despite the potential benefits of treatment in terms of symptom control, estimates of adherence to IBD medication range from 16 to 66% (Hommel, Mackner, Denson, & Crandall, 2008) . Some of this variation may be accounted for by the method of assessment (e.g., pill counts, blood levels, daily diaries); however, it has also been documented that adolescents with IBD perceive different barriers to adherence based on treatment type (Greenley, Stephens, Doughty, Raboin, & Kugathasan, 2010) . This makes intuitive sense given the range of options available for treating IBD, which vary substantially in terms of dose frequency, timing, and delivery method. For example, some treatments involve only one dose every 8 weeks, but are delivered via infusion during lengthy clinic visits (e.g., intravenous immunosuppressants). Other treatments (e.g., anti-inflammatory medications) are administered at home and involve oral medications dosed multiple times per day or once-daily medication given rectally. Some evidence suggests that treatment regimens involving more frequent or intensive dosing schedules (e.g., several pills taken orally in multiple doses each day) have particularly poor rates of adherence (e.g., orally administered anti-inflammatory medications; Bernal et al., 2006) . In addition to pragmatic differences related to dosing, some regimens put patients at risk of significant physical and/or emotional side effects (e.g., steroids; Cross, Lapshin, & Finkelstein, 2008) . All of these factors may affect patients' perception of treatment burden and, consequently, their willingness to adhere to prescribed treatments.
The Health Beliefs Model (HBM) can help explain the variability in rates of adherence noted above. The HBM suggests that families are engaged in a fluid process of continually weighing perceived treatment burden against perceived symptom severity in making decisions about treatment adherence (Janz, Champion, & Strecher, 2002) . Adams and colleagues (2004) have applied this model to pediatric asthma, an inflammatory condition similar to pediatric IBD in terms of its unpredictable symptom course and lack of one-to-one correspondence between adherence to medication regimen and clinical outcome. These authors suggest that adherence can be viewed as a continual balancing act analogous to a harmonic curve with severe symptoms first leading to perfect use (or even overuse) of medication until symptoms improve, followed by a shift to less adherent use of medications when the perceived burden shifts from the symptoms to the treatment, and so on. This continual process of shifting burden and adherence theoretically continues until a perceived balance between symptom and treatment burden is obtained. Preliminary support for this conceptualization has been demonstrated using a survey of caregivers that indicated $30% of families intentionally changed their child's medication regimen, generally increasing a child's asthma medication when symptoms flare and decreasing medications when side-effects present and/or symptoms improve (Graves, Adams, Bender, Simon, & Portnoy, 2007) .
It seems possible that a similar balancing act occurs in pediatric IBD. As appears to be the case in pediatric asthma, patients with IBD may begin to intentionally modify their medication regimen in search of a balance between their disease and perceived treatment burden. This type of purposeful experimentation would represent a different sort of nonadherence than simple forgetting, or ''accidental'' nonadherence. One label that has been used to describe this type of behavior is volitional nonadherence, defined as purposefully cutting back, missing, or altering doses outside what is allowed within a prescribed treatment plan, resulting in either partial or total nonadherence (Wroe, 2002) . Although this concept has not yet been studied in pediatric IBD, studies on adult IBD suggest that disease course and associated treatment regimens may encourage rates of volitional nonadherence similar to those documented in pediatric asthma. In the few studies that have made the distinction between accidental and volitional nonadherence, 8-36.5% of adult patients who fail to perfectly adhere to their IBD medication reported doing so intentionally (Bernal et al., 2006; Sewitch et al., 2003) . Specifically, participants reported intentionally altering their medication regimen to obtain more desirable physical, emotional, or social outcomes (Bernal et al., 2006) . Thus, it seems that concepts of disease and treatment burden extend beyond physical symptoms and/or side effects to also include perceptions of social and emotional quality of life (QOL).
Consistent with the HBM, preliminary data from pediatric asthma and adult IBD suggest that balancing physical, emotional, and social QOL may be the ultimate goal of volitional nonadherence. Although nonadherence in children with IBD may occur for different reasons as compared to adults, studies of barriers to medication adherence in pediatric IBD also provide some qualitative evidence to support this theoretical balancing act. Specifically, side effects, complexity of the treatment regimen, and symptom control appear to play a role in families' medication adherence behavior (Greenley et al., 2010; . Furthermore, degree of overall adherence has been found to vary with disease severity (Oliva-Hemker, Abadom, Cuffari, & Thompson, 2007) , as well as with physical and social QOL (Hommel, Davis, & Baldassano, 2008) . These few studies appear to support the application of the HBM, and the concept of volitional nonadherence specifically, to the pediatric IBD population.
To date, however, most research on adherence in pediatric IBD has treated adherence as a single unitary construct with ''forgetting'' consistently identified as the most frequent barrier to adherence Ingerski, Baldassano, Denson, & Hommel, 2009; Mackner & Crandall, 2005) . It remains unclear whether: (1) volitional and accidental nonadherence are distinct concepts in pediatric IBD; and, if so, (2) whether this distinction is an important one. In other words, do volitional and accidental nonadherence demonstrate similar relationships with disease severity and QOL or are there important Volitional and Accidental Nonadherence in IBD 117 differences that are masked when studied together as a single unitary construct? Furthermore, if different patterns of association are found between adherence type and disease severity or QOL, does volitional nonadherence appear to be adaptive, as suggested by some researchers in the past (i.e., ''adaptive noncompliance''; Deaton, 1985) , leading to a better balance between perceived disease and treatment burden for children with pediatric IBD (i.e., higher QOL while maintaining relatively low disease severity)? Answers to these questions may help to better inform our understanding of adherence both in planning future research and in intervening on the individual clinical level.
The current study advances the existing literature by attempting to replicate in pediatric IBD the existence of volitional nonadherence as previously documented in pediatric asthma and adult IBD. Specifically, we expected reported rates of volitional nonadherence to be similar for pediatric IBD in comparison to pediatric asthma (30%) and adult IBD (8-36.5%). Furthermore, given the limited research existing to support a specific hypothesis, we aimed to examine in a preliminary and exploratory fashion the relationship between nonadherence type (volitional and accidental), disease severity, and QOL (physical, emotional, and social) in the pediatric IBD population.
Method Participants
Participants were parent/child dyads recruited from a large Midwestern children's hospital. Dyads were eligible if the child was between the ages of 1 and 17 years inclusive, had been given a diagnosis of inflammatory bowel disease (IBD) at least 1 year prior to the date of recruitment, and both the parent and adolescent (when applicable) participants were able to read in English. In total, 116 families were approached; of these, 5 families were deemed ineligible prior to data collection (3 patients had been diagnosed less than 1 year previously and 2 patients had an indeterminate diagnosis) and 11 families refused participation (primarily citing time constraints). This yielded a final sample of 100 dyads with a recruitment rate of 90%. Of the children who participated, 75% were diagnosed with Crohn's disease and 25% were diagnosed with ulcerative colitis. The final sample represented a wide age range (3-17 years old; M ¼ 13.6 AE 3.4 years) and, consistent with the population served by this clinic, were racially homogeneous (92% Caucasian, 7% African American, and 1% other). Participants included roughly equal numbers of males (54%) and females (46%). The mean time since diagnosis was 3.4 AE 2.2 years.
Measures

IBD Care Behaviors
A 65-item measure of adherence to IBD medication was developed by the authors for use in this study. The content and format were adapted from a questionnaire used in previous work with pediatric asthma (Graves et al., 2007) and revised through a series of standard stages in questionnaire development (e.g., item development, expert review of content, and piloting with families). In addition to a parent self-report version, a parallel version was created to allow direct assessment of adolescent participants. Adolescents (broadly defined for the purpose of this study as 11-17 years inclusive) were considered directly because they are likely to be more autonomous in their medication behavior than preadolescent children (Anderson, Ho, Brackett, Finkelstein, & Laffel, 1997) , with the lower age limit specified as 11 years to correspond to the sixth-grade reading level of the measure and the typical time of entrance into middle school. The IBD Care Behaviors (IBD-CB) uses a series of true/false and multiple choice items to ask all families about the frequency of accidental and volitional nonadherence, as well as specific modifications the family has made to prescribed treatments over the past 3 months. In addition, families who endorse at least one prior occurrence of volitional nonadherence complete the remainder of the measure investigating general motivating factors and methods used to volitionally change the medication regimen. The IBD-CB is not designed to yield scales, but rather to provide item-level information on a broad range of adherence behaviors. Consistent with this, frequency of accidental and volitional nonadherence to the child's medication regimen was determined for the current study based on response to a single multiple-choice item each, using the following scale: ''Every day,'' ''Several times a week,'' ''Several times a month,'' ''About once a month,'' ''Several (5-9) times a year,'' ''A few (3-4) times a year,'' ''About twice (2) a year,'' ''About once (1) a year,'' ''Once every few years,'' and ''Not at all.'' Pediatric Quality of Life Scale-Version 4.0 The Pediatric Quality of Life Scale-Version 4.0 (PedsQL) (Varni, Seid, & Kurtin, 2001 ) is a reliable and valid 23-item questionnaire that measures parent report and adolescent self-report of health-related QOL on parallel forms. Items can be recoded from 100 to 0 on 25-point intervals and averaged to produce two broad-band scales, Physical Functioning and Psychosocial Functioning (comprised of Emotional, Social, and School Functioning domains). Higher scores indicate better QOL in each area. The current sample yielded good reliability coefficients for both parent report and adolescent self-report on the Physical ( ¼ .84 and .85, respectively) and Psychosocial ( ¼ .87 and .87, respectively) Functioning scales. Previous work examining QOL in pediatric IBD has demonstrated different associations between the Physical and Psychosocial Functioning scales by method of nonadherence assessment . Given our interest in the potential differential impact of nonadherence type on physical and psychosocial aspects of QOL (as a proxy for perceived disease and treatment burden), the two broad-band scales were examined rather than the total score.
Pediatric Crohn's Disease Activity Index
The Pediatric Crohn's Disease Activity Index (PCDAI) (Hyams et al., 1991 ) is a well-validated measure of disease activity in pediatric patients with Crohn's disease. The scale is scored using a 0-100 metric and includes a composite of information from the child's IBD follow-up visits, number of inpatient hospital days, number of follow-up phone calls, most recent IBD treatment plan, and physician rating of IBD severity. Using the method of scoring proposed by the developers, the PCDAI breaks out into three classification categories, as follows: scores of 10 indicate clinical remission; scores of 11-30 indicate mild disease activity; and scores >30 indicate moderate to severe disease activity (Hyams et al., 1991) . The total score was examined as a measure of IBD disease severity.
Pediatric Ulcerative Colitis Activity Index
The Pediatric Ulcerative Colitis Activity Index (PUCAI) (Turner et al., 2007 ) is a well-validated measure of disease activity in pediatric ulcerative colitis patients. The measure was originally developed via Delphic polling and validated against other measures of ulcerative colitis and physician ratings of global functioning. The PUCAI also has good inter-observer agreement and test-retest reliability. The measure is scored on a 0-85 scale and can be broken down into four disease severity categories. Scores <10 indicate no disease activity, 10-34 indicates mild disease activity, 35-64 indicates moderate disease activity, and scores !65 indicate severe disease activity (Turner et al., 2007) . Prior to data analysis, the PUCAI was transformed to a 0-100 scale for consistency with the range of the PCDAI and to facilitate examination of the total score as a measure of IBD disease severity.
Procedure
Participants were recruited from a gastroenterology clinic at their regularly scheduled follow-up or treatment visits for IBD. Research personnel (who were not involved in the IBD treatment team) talked with eligible families during a break in their visit and inquired about their interest in study participation. Both permission/consent and assent were obtained from interested dyads, as appropriate. Families were assured that all responses would be kept confidential and would not be shared with their child's doctor or nurses in the IBD treatment team. When an adolescent was available to complete self-report, the parent and adolescent completed forms in separate rooms or research personnel remained in the room with the family to ensure independent responding. Ratings of disease severity on the PCDAI/PUCAI were gathered from healthcare providers blind to family responses following completion of study measures. All procedures were approved by the institutional review board of the participating hospital.
Data Analysis Plan
Measures were completed by all participating parents and adolescents, with <1% missing data. Frequency statistics first were calculated for items describing the frequency of accidental and volitional nonadherence to medication regimen by rater. A weighted-kappa statistic was calculated to determine the level of agreement between multiple raters (i.e., parents and adolescents) on frequency of medication nonadherence by type. The weighted kappa allows more flexibility in determining agreement by weighting misses in closely related categories more heavily than misses in categories further apart (Cohen, 1968) . Furthermore, Spearman's rho coefficients were calculated for volitional and accidental nonadherence within rater in an effort to determine the degree of association between the two adherence types and, in particular, whether they represent conceptually distinct constructs for adolescents and parents. A series of linear regressions then were used to examine the potential differential impact of accidental versus volitional nonadherence on physical and psychosocial QOL, as well as on IBD disease severity. Reported frequency of both accidental and volitional nonadherence were included or excluded in the regression model in a single step based on preset criteria for forward entry (probability-of-F-to-enter .05). Age and gender were investigated as possible covariates and entered into regressions during Step 1, prior to model building, as appropriate. All statistical analyses described above were conducted using the full sample using SPSS 17.0 with significance levels set at p < .05. No correction for multiple tests was employed given the exploratory nature of this study. Finally, for families endorsing at least one past volitional medication change, descriptive statistics were calculated to begin characterizing the motivating factors and methods that families use to volitionally change the child's Volitional and Accidental Nonadherence in IBD 119 medication regimen in an effort to better elucidate any associations found.
Results
Frequency of Medication Nonadherence
Accidental Nonadherence The majority of adolescents and parents (73.1 and 70.1%, respectively) reported some occurrence of accidental nonadherence to the child's prescribed medication regimen. When asked to identify how frequently accidental nonadherence occurred, the top three responses for both raters were the same, although the rank order differed. Parents most often reported accidental nonadherence occurring about once per month (19.2%), a few times per year (15.2%), or several times per month (12.1%). Adolescents most often reported accidental nonadherence occurring several times per month or about once per month (both 19.2%) or a few times per year (14.1%). Parent-adolescent dyads demonstrated moderate agreement on frequency of accidental nonadherence ( ¼ .56).
Volitional Nonadherence
About one-third of parents and adolescents (30 and 35%, respectively) reported some occurrence of volitional nonadherence to the child's prescribed medication regimen. Parents most often endorsed making an intentional medication change on their own about once (8.1%) or twice (6.1%) per year or less (6.1%). Adolescents most often endorsed having made an intentional medication change on their own about once (7.7%) or twice (7.7%) per year. Parent-adolescent dyads demonstrated fair agreement on frequency of volitional nonadherence ( ¼ .40).
Association Between Accidental and Volitional Nonadherence A significant association was not found between frequency of volitional versus accidental nonadherence for either parent ( ¼ .00, p ¼ .99) or adolescent report ( ¼ .13, p ¼ .27) data.
Association of Accidental and Volitional Nonadherence with Disease Severity and Quality of Life
Preliminary Analyses
Descriptive statistics for all disease severity and QOL variables for the complete sample are presented in Table I . Simple correlations indicated no significant associations between child age and disease severity or QOL variables. Independent t-tests for child gender yielded a significant mean difference for adolescent self-(t ¼ 3.10, p < .05) and parent-(t ¼ 2.29, p < .05) reported physical QOL and adolescent self-reported psychosocial QOL (t ¼ 2.11, p < .05), such that boys were experiencing better QOL than girls in these areas. To control for this effect, child gender was entered into the appropriate regression analyses predicting physical and psychosocial QOL as indicated in the data analysis plan. Adherence and QOL ratings were examined separately within rater (i.e., parent self-report of adherence with parent report of adolescent QOL; adolescent self-report of adherence with adolescent self-report of QOL) given the good, but imperfect, inter-rater agreement on adherence already noted.
Disease Severity
Volitional nonadherence contributed significant variance to the prediction of disease severity within the parent (R 2 Á ¼ .10, F[1, 97] ¼ 10.22, p < .005) and the adolescent (R 2 Á ¼ .08, F[1, 76] ¼ 6.88, p < .05) models, with more frequent volitional nonadherence associated with greater disease severity scores in both models. Frequency of accidental nonadherence did not meet criteria to enter either model.
Physical QOL
For both the parent and adolescent models, child gender was controlled in Step 1 as previously described. Neither accidental nor volitional nonadherence met criteria to enter the parent or adolescent report model.
Psychosocial QOL
Volitional nonadherence contributed significant variance to the prediction of child psychosocial QOL within the parent 
Examination of Motivating Factors and Methods for Volitional Nonadherence
Descriptive statistics were calculated to begin characterizing the motivating factors and methods that families use to volitionally change the child's medication regimen in an effort to better understand the association of volitional nonadherence with disease severity and psychosocial QOL, as described above. The following analyses are based only on the parents and adolescents who reported making at least one volitional change to the child's prescribed medication regimen in the past three months, except where noted. 
Factors Motivating Volitional Nonadherence
Methods Used in Volitional Nonadherence
When the entire sample was asked about volitional changes in the child's prescribed treatment over the past 3 months, families most often reported decreasing medications, with few exceptions (see Table III for details by medication type). Decreasing a medication most commonly involved skipping doses, followed in frequency by stopping a medication altogether, and, lastly, by decreasing the amount of medication taken per dose. Increasing a medication involved scheduling a treatment more frequently than prescribed (i.e., for intravenous immunosuppressants), increasing the amount of medication taken per dose, increasing the number of doses, or starting a previously discontinued (or never prescribed) medication; a specific pattern was not possible to distinguish, however, given the relative infrequency of families increasing medication in the current sample.
The vast majority of both parents and adolescents who endorsed at least one prior occurrence of volitional nonadherence reported getting information from their doctor (PR ¼ 94.4%, SR ¼ 82.1%) as informing their own decisions about changing the child's prescribed IBD medication regimen. Parents and adolescents also frequently reported: talking to their doctor to get information before making changes on their own (PR ¼ 73%, SR ¼ 42.9%); telling the doctor after making changes on their own (PR ¼ 58.3%, SR ¼ 46.4%); and using the child's physical symptoms to inform their own decisions about changing the child's prescribed IBD regimen (PR ¼ 44.7%, SR ¼ 42.9%; see Table IV for a comprehensive list of methods endorsed by families).
Discussion
The current study examined accidental and volitional nonadherence in a pediatric IBD population. While previous scholarship has measured nonadherence as a unitary construct Mackner & Crandall, 2005) , the current data indicate that parents and children view volitional and accidental nonadherence as different constructs. Families agreed reasonably well on the frequency of both nonadherence types and minimal overlap was seen between the two types based on either parent self-report or adolescent self-report. Furthermore, families were thoughtful enough about their nonadherence to retrospectively report on why and how they make intentional changes to the child or adolescent patient's prescribed IBD medication regimen.
As expected, reported rates of volitional nonadherence in our pediatric IBD sample (30-35%) were similar to those previously documented in pediatric asthma (30%) and adult IBD (8-36.5%). Adding to the limited number of previous reports, this study found that nonadherence is associated with greater disease activity and poorer parent-reported psychosocial QOL. However, this study extends those findings by demonstrating a differential association by nonadherence type. Specifically, frequency of accidental nonadherence was unrelated to disease activity or any specific QOL area examined, while frequency of volitional nonadherence was significantly associated with greater disease activity and poorer parent-reported psychosocial QOL. More narrowly defining types of nonadherence in the current investigation appears to have allowed for a more thorough understanding of the associations with disease and QOL outcomes.
Additional strengths of the current study include use of multiple raters (i.e., parents, adolescents, and healthcare providers) and multiple indicators of clinical outcome (i.e., disease severity, physical QOL, and psychosocial QOL), with extra steps taken to ensure confidentiality and independence of responding. This study also benefits from a relatively large sample of parent-child dyads within pediatric IBD, which made it possible to identify some significant associations despite the relatively small proportion of families who reported engaging in volitional nonadherence and resulting limited statistical power. Associations between nonadherence type and clinical outcome variables were generally consistent across the parent and adolescent regression models, with the exception being the prediction of psychosocial QOL, which may have been particularly impacted by power issues given the need to control for gender in
Step 1 of the adolescent model. This single difference aside, the overall consistency observed between raters lends greater confidence to the results found in this exploratory study.
Several limitations of the current study also warrant mention. Although the sample size was relatively large and representative of the clinic population at the sponsoring institution, the fact that the sample was derived at one site and was racially homogenous limits potential generalizability to all pediatric patients with IBD. In addition, the relatively small proportion of families who endorsed having made at least one volitional medication change in the past limited our ability to examine differences among specific subgroups (e.g., gender, age, and PCDAI/PUCAI classification), medication regimens, or other variables of interest. Future work will likely need to be multi-site in order to accrue numbers sufficient to allow examination of these more discrete variables. Finally, this was cross-sectional Get information from internet 5.4% (n ¼ 2) Did not understand tx plan 11.5% (n ¼ 3)
Did not understand tx plan 0% (n ¼ 0) Get information from internet 7.1% (n ¼ 2)
Base advice from other parents 0% (n ¼ 0) Base advice from other parents 3.6% (n ¼ 1)
Note. Percentages based on subgroup of families endorsing at least one prior occurrence of volitional nonadherence within the past 3 months. Percentages vary slightly based on number of respondents per item.
work relying on retrospective reports by parents and adolescents to determine frequency of nonadherence. Although necessary as a first step, it would be helpful to have more objective corroboration (e.g., pill counts, blood levels, etc.) of reported adherence patterns in future prospective, longitudinal work. While it is beyond the scope of this cross-sectional work to examine the direction and mechanism of the associations found, our preliminary data regarding the family motivations and methods for volitional change suggest several possibilities that warrant mention as future avenues for study. Greater disease activity and/or negative psychosocial QOL associated with disease burden may drive some families to initiate changes to the child's prescribed IBD medication regimen. Indeed, ''wanting better control'' of the child's IBD was one of the most commonly endorsed reasons for family-initiated change in the current study across both parents and adolescents. However, more than half of parents and adolescents who reported being volitionally nonadherent identified ''got better'' as the motivating reason for this intentional change. This echoes previous literature indicating that ''getting better'' is a common barrier to perfect adherence and that children with Crohn's disease are three to four times more likely to be nonadherent to medication when they are asymptomatic (Oliva-Hemker et al., 2007) . Thus, results from the current study leave open the possibility that directionality may not be the same for all families and, as suggested by the HBM, may be a more continuous process of adjustment in search of the best balance of diseaseand treatment-related burden for a particular child and family.
Furthermore, the current study extends previous findings by suggesting that the motivation for nonadherence may come from a simultaneous decreasing perception of disease severity and increasing perception of treatment burden. For adolescents, social and emotional QOL appears particularly salient in motivating volitional changes. Unfortunately, the direction of associations found suggests that these changes may ultimately result in increased IBD symptoms or flares and unforeseen negative consequences for psychosocial QOL. Future longitudinal work examining the process of family-initiated changes, with particular emphasis on timing and order of effects on disease severity and psychosocial QOL, will be helpful in disentangling these relationships and identifying appropriate targets and strategies for clinical intervention.
Overall, findings from this initial investigation suggest that nonadherence, and the relationship with disease severity and QOL, may be more complex for children with IBD than understood through previous work. Consistent with the HBM, a substantial minority of families appear to modify the prescribed treatment regimen intentionally in search of a balance between disease and treatment burden. If these different types of adherence continue to demonstrate unique patterns of association with outcome in confirmatory work, it may be useful to model adherence as a dynamic multi-faceted process throughout treatment rather than as a dichotomous present/absent variable in future research and clinical endeavors. A better understanding of the apparent complexities of the family decision-making process around adherence will, in the end, allow for more targeted and effective clinical interventions to improve the lives of children and adolescents with IBD.
